Biosolution Co., Ltd. (CEO Song-Seon Jang), a specialized research and development company for cell therapy products, is reinforcing the capabilities of the human tissue model business. The company announced on the 25th that it will complete the research and development of new products in the human tissue model sector and launch the oral mucosa model (SoluOral™) and the bronchial mucosa model (SoluAirway™).
The oral mucosa model (SoluOral™) released by the company is composed of untransformed oral mucosa cells and has structural characteristics similar to that of the actual human oral mucosa. This product is developed for oral mucosal irritation test, safety evaluation of oral products, and biocompatibility evaluation of dental materials, and can be widely used to develop toothpaste, mouthwash, and dental implant materials. Plan.
In addition, the bronchial mucosa model (SoluAirway™) is a product obtained by recovering the non-mucosal epithelial cells of tissues discarded in the course of treatment, securing safety against viruses and microorganisms, and then culturing them in three dimensions. It will be used for drug delivery and metabolism studies, air pollution assessment, and chronic respiratory disease studies. The bronchial mucosa model has already participated in the safety evaluation of humidifier disinfectant by the Ministry of Environment and the inhalation toxicity evaluation of the Korea Centers for Disease Control and Prevention from the development stage, and is currently in the stage of consultation with domestic medical institutions for research on drug delivery and metabolism in the body. have.
A company official said, “The human tissue model is used for non-clinical efficacy and toxicity evaluation, such as animal testing. It is an intermediate stage between non-clinical and clinical, and errors in animal testing can be improved.” “In Korea, mainly cosmetic testing. Although the market is formed, the demand for human tissue models is gradually expanding to medical devices and pharmaceuticals, and the growth potential of the market is very high due to the change in social perception of animal testing.”
The company is also accelerating research on microstructure models to be used in basic medical research. The plan is to rapidly build a lineup by developing a dopamine neuron model for Parkinson’s disease and treatment, a pancreatic model for diabetes research, and a liver model for hepatitis and liver toxicity evaluation.
Meanwhile, the skin model developed by the company has completed the application for registration in the International Toxicity Assessment Guideline (OECD TG) in November 2019 and is waiting for the results, and is strengthening the sales of Kati Life, a cartilage-derived cartilage joint therapy.